Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta

Trial Profile

Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2018

At a glance

  • Drugs Damoctocog alfa pegol (Primary) ; Efmoroctocog alfa
  • Indications Haemophilia A
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 04 May 2018 Planned End Date changed from 9 Apr 2018 to 11 Jun 2018.
    • 02 Mar 2018 Planned End Date changed from 11 May 2018 to 9 Apr 2018.
    • 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top